RO5083945

DRUG5 trials

Sponsors

Hoffmann-La Roche

Conditions

Colorectal CancerHead and Neck CancerNeoplasmsNon-Squamous Non-Small Cell Lung Cancer

Phase 1

A Dose-Escalation Study of RO5083945 in Patients With Metastatic and/or Locally Advanced Malignant Epidermal Growth Factor Receptor (EGFR)+ Solid Tumors.

CompletedNCT00721266

Hoffmann-La RocheNeoplasms

Start: 2008-06-30End: 2011-06-30Updated: 2016-11-02

A Study of Pharmacodynamics of RO5083945 in Patients With Head and Neck Squamous Cell Carcinoma

CompletedNCT01046266

Hoffmann-La RocheHead and Neck Cancer

Start: 2009-11-30End: 2012-06-30Updated: 2016-09-14

A Study of RO5083945 in Combination With Cisplatin and Gemcitabine or Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer of Squamous Histology Who Have Not Received Prior Chemotherapy for The Metastatic Disease

WithdrawnNCT01702714

Hoffmann-La RocheNon-Squamous Non-Small Cell Lung Cancer

Start: 2014-07-31End: 2016-02-29Updated: 2016-11-04

Phase 2

A Study of RO5083945 in Combination With Chemotherapy Versus Chemotherapy Alone in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

CompletedNCT01185847

Hoffmann-La RocheNon-Squamous Non-Small Cell Lung Cancer

Start: 2010-11-30End: 2012-09-30Updated: 2016-01-01

A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer

CompletedNCT01326000

Hoffmann-La RocheColorectal Cancer

Start: 2011-04-30End: 2013-12-31Updated: 2022-11-17

Related Papers

An exploratory, open-label, randomized, multicenter study to investigate the pharmacodynamics of a glycoengineered antibody (imgatuzumab) and cetuximab in patients with operable head and neck squamous cell carcinoma.

2017-11-0118 citations

GAIN-(C): Efficacy and safety analysis of imgatuzumab (GA201), a novel dual-acting monoclonal antibody (mAb) designed to enhance antibody-dependent cellular cytotoxicity (ADCC), in combination with FOLFIRI compared to cetuximab plus FOLFIRI in second-line KRAS exon 2 wild type (e2WT) or with FOLFIRI alone in mutated (e2MT) metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology2015-01-2013 citations